Senores Pharmaceuticals IPO
IPO Details
- Open Date
20 Dec 2024
- Close Date
24 Dec 2024
- IPO
Price Range
₹ 372 to ₹ 391
- IPO
Size
₹ 582.11 Cr
- Listing Exchange
BSE NSE
- Listing Date
30 Dec 2024
IPO Timeline
Senores Pharmaceuticals IPO Subscription Status
| Date | QIB | NII | Retail | TOTAL |
|---|---|---|---|---|
| 20-Dec-24 | 0.01 | 1.76 | 7.83 | 1.93 |
Last Updated: 20 December 2024 5:58 PM by 5Paisa
Senores Pharmaceuticals IPO is set to open on 20 December 2024 and will close on 24 December 2024. Senores Pharmaceuticals develops and manufactures pharmaceutical products for regulated markets in the US, Canada, UK, and emerging markets.
The IPO is a combination of a fresh issue of 1.28 Cr. shares, aggregating to ₹500.00 Cr and an offer for sale of 0.21 Cr. shares, aggregating to ₹82.11 Cr. The price range is set at ₹372 to ₹391 per share and the lot size is 38 shares.
The allotment is scheduled to be finalised on 26 December 2024. It will go public on BSE NSE, with a tentative listing date of 30 December 2024.
Equirus Capital Pvt Ltd, Ambit Pvt Ltd, Nuvama Wealth Management Ltd are the book running lead managers, while Link Intime Ltd is the registrar.
Senores Pharmaceuticals IPO Size
| Types | Size |
|---|---|
| Total IPO Size | ₹582.11 Cr. |
| Offer For Sale | ₹82.11 Cr. |
| Fresh Issue | ₹500.00 Cr. |
Senores Pharmaceuticals IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 38 | ₹14,136 |
| Retail (Max) | 13 | 494 | ₹183,768 |
| S-HNI (Min) | 14 | 532 | ₹197,904 |
| S-HNI (Max) | 67 | 2,546 | ₹947,112 |
| B-HNI (Min) | 68 | 2,584 | ₹961,248 |
Senores Pharmaceuticals IPO Reservation
| Investors Category | Subscription (times) | Shares Offered | Shares bid for | Total Amount (Cr.)* |
|---|---|---|---|---|
| QIB | 0.01 | 44,43,817 | 28,766 | 1.125 |
| NII (HNI) | 1.76 | 22,21,909 | 39,14,836 | 153.070 |
| Retail | 7.83 | 14,81,272 | 1,15,97,448 | 453.460 |
| Total** | 1.93 | 81,46,998 | 1,56,87,616 | 613.386 |
*The "Shares Offered" and "Total Amount" are calculated using the upper limit of the issue price range.
**Shares allocated to anchor investors (or market makers) are excluded from the total number of shares offered.
Senores Pharmaceuticals IPO Anchor Allocation
| Anchor Bid Date | 19 December, 2024 |
| Shares Offered | 66,65,725 |
| Anchor portion Size (In ₹ Cr.) | 260.63 |
| Anchor lock-in period end date for 50% shares (30 Days) | 25 January, 2025 |
| Anchor lock-in period end date for remaining shares (90 Days) | 26 March, 2025 |
1. Investment in Havix Group, Inc. (subsidiary) for setting up a sterile injection manufacturing facility in Atlanta and repayment/pre-payment of its borrowings.
2. Repayment/pre-payment of the Company’s borrowings.
3. Funding the Company’s working capital requirements.
4. Investment in Senores Pharmaceuticals Inc. (SPI) and Ratnatris Pharmaceutical Private Limited (Ratnatris) for their working capital needs.
5. Funding inorganic growth through acquisitions and other strategic initiatives.
6. General corporate purposes.
Senores Pharmaceuticals Limited, founded in December 2017, develops and manufactures pharmaceutical products for regulated markets in the US, Canada, UK, and emerging markets. With 55 product launches, including antibiotics and anti-fungal treatments, it operates R&D facilities in India and the US. The company’s strengths include US FDA-approved manufacturing, long-term marketing agreements, and a strong management team.
Established in: 2017
Managing Director: Mr. Swapnil Jatinbhai Shah
Peers
Ajanta Pharmaceuticals Ltd
Alembic Pharmaceuticals Ltd
Caplin Point Laboratories Ltd
Gland Pharma Limited
Strides Pharma Science Ltd
| Particulars (in Rs. Crores) | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | 14.63 | 39.02 | 217.34 |
| EBITDA | 2.41 | 16.35 | 44.41 |
| PAT | 0.99 | 8.43 | 32.71 |
| Particulars (in Rs. Crores) | FY22 | FY23 | FY24 |
|---|---|---|---|
| Total Assets | 59.15 | 131.05 | 621.88 |
| Share Capital | 8.74 | 9.82 | 30.51 |
| Total Borrowings | 14.21 | 60.76 | 248.38 |
| Particulars (in Rs. Crores) | FY22 | FY23 | FY24 |
|---|---|---|---|
| Net Cash Generated From / (used in) operating activities | -10.45 | -1.08 | -19.88 |
| Net Cash Generated From / (used in) investing activities | -24.44 | -48.29 | -54.66 |
| Net Cash Generated From / (used in) financing activities | 36.46 | 46.25 | 86.98 |
| Net Increase (Decrease) In Cash And Cash Equivalents | 1.58 | -3.12 | 12.45 |
Strengths
1. US FDA-approved manufacturing facility ensures compliance with global regulatory standards.
2. Robust product portfolio catering to both regulated and emerging markets.
3. Strong presence in key therapeutic areas, including antibiotics and anti-fungal treatments.
4. Well-established long-term marketing agreements with pharmaceutical companies in the US, Canada, and UK.
5. Experienced management team with expertise in the global pharmaceutical industry.
Risks
1. Heavy reliance on a few key markets for revenue generation.
2. Limited geographic diversification outside of 43 countries.
3. Potential vulnerability to regulatory changes in key markets.
4. Dependence on partnerships for distribution may affect market control.
5. High competition in the pharmaceutical industry could limit growth opportunities.
in 3
easy steps
Using 5paisa App or
Website
to block Payment
Open Free Demat Account
Be a part of 5paisa community - The first listed discount broker of India.
By proceeding, you agree to all T&C*
FAQs
Senores Pharmaceuticals IPO opens from 20 December to 24 December 2024.
The size of Senores Pharmaceuticals IPO is ₹582.11 Cr.
The price of Senores Pharmaceuticals IPO is fixed at ₹372 to ₹391 per share.
To apply for Senores Pharmaceuticals IPO, follow the steps given below:
● Login to your 5paisa account and select the issue in the current IPO section
● Enter the number of lots and the price at which you wish to apply for the Senores Pharmaceuticals IPO.
● Enter your UPI ID and click on submit. With this, your bid will be placed with the exchange.
You will receive a mandate notification to block funds in your UPI app.
The minimum lot size of Senores Pharmaceuticals IPO is 38 shares and the investment required is ₹14,136.
The share allotment date of Senores Pharmaceuticals IPO is 26 December 2024.
The Senores Pharmaceuticals IPO will be listed on 30 December 2024.
Equirus Capital Pvt Ltd, Ambit Pvt Ltd, Nuvama Wealth Management Ltd are the book running lead managers for Senores Pharmaceuticals IPO.
Senores Pharmaceuticals plans to utilise the raised capital from the IPO for:
1. Investment in Havix Group, Inc. (subsidiary) for setting up a sterile injection manufacturing facility in Atlanta and repayment/pre-payment of its borrowings.
2. Repayment/pre-payment of the Company’s borrowings.
3. Funding the Company’s working capital requirements.
4. Investment in Senores Pharmaceuticals Inc. (SPI) and Ratnatris Pharmaceutical Private Limited (Ratnatris) for their working capital needs.
5. Funding inorganic growth through acquisitions and other strategic initiatives.
6. General corporate purposes.
Contact Information
Senores Pharmaceuticals
Senores Pharmaceuticals Limited
1101 to 1103, 11th floor,
South Tower, ONE 42 oppositeJayantilal Park,
Ambali Bopal Road, Ahmedabad,-380054
Phone: +91-79-29999857
Email: cs@senorespharma.com
Website: https://senorespharma.com/
Senores Pharmaceuticals IPO Register
Link Intime India Private Ltd
Phone: +91-22-4918 6270
Email: senorespharma.ipo@linkintime.co.in
Website: https://linkintime.co.in/Initial_Offer/public-issues.html
Senores Pharmaceuticals IPO Lead Manager
Equirus Capital Private Limited
Ambit Private Limited
Nuvama Wealth Management Limited